Department of Biomedical Engineering, Duke University, Durham, NC, United States.
Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United States; Department of Orthopedic Surgery, Washington University in St. Louis, St. Louis, MO, United States.
J Control Release. 2018 Aug 10;283:76-83. doi: 10.1016/j.jconrel.2018.05.029. Epub 2018 May 26.
Determine the effects of arthritis on the trans-synovial clearance of small and large model compounds following local delivery to the knee joint in a rat model.
Intra-articular delivery was studied in rat knee joints in an osteoarthritis model of joint instability (medial collateral ligament and meniscus transection model or MMT). Fluorescently-labeled 10 kDa or 500 kDa dextran was injected in the arthritic or unoperated control (naive) joints 3 weeks after surgical destabilization, and the temporal clearance pattern was evaluated via in vivo regional fluorescence imaging, dextran concentrations in plasma and draining lymph nodes, and by quantification of fluorescence in histological synovium sections. Together these data were used to evaluate the effect of osteoarthritis and solute size on the rate of drug clearance from the joint.
Clearance of 10 kDa dextran from the joint space quantified using in vivo fluorescence imaging of the knee joint region was not significantly different between naive and MMT joints. In contrast, clearance of 500 kDa dextran was significantly reduced for MMT joints when compared to naive joints by fluorescence in vivo imaging. Drug accumulation in lymph nodes and plasma were lower for the 500 kDa dextran as compared to 10 kDa dextran, and lymph node levels were further reduced with the presence of osteoarthritis. Furthermore, synovium was significantly thicker in MMT joints than in naive joints and image analysis of joint tissue sections revealed different trans-synovial distributions of 10 and 500 kDa dextran.
Large macromolecules were retained in the arthritic joint longer than in the healthy joint, while smaller molecules were cleared similarly in healthy and arthritic joints. In vivo fluorescence imaging, plasma and lymph node concentrations, and spatial distributions of drug fluorescence identified differences in higher molecular weight clearance between naive and arthritic disease states. Findings may relate to a thickening of synovium for joints with induced arthritis, and support the concept that intra-articular drug delivery effectiveness may vary with the state of joint pathology.
在关节不稳定的大鼠模型(内侧副韧带和半月板切断模型或 MMT)中,确定关节炎对局部膝关节给药后小和大模型化合物经滑膜清除的影响。
在关节炎模型(MMT)中,研究了关节内给药对大鼠膝关节的影响。在手术不稳定后 3 周,向关节炎或未手术对照(未处理)关节内注射荧光标记的 10 kDa 或 500 kDa 葡聚糖,并通过体内局部荧光成像、关节腔外渗液和引流淋巴结中的葡聚糖浓度以及组织学滑膜切片中荧光的定量来评估清除的时间模式。这些数据共同用于评估骨关节炎和溶质大小对药物从关节清除率的影响。
使用膝关节区域的体内荧光成像对关节腔中 10 kDa 葡聚糖的清除率在未处理和 MMT 关节之间没有显著差异。相比之下,与未处理关节相比,体内荧光成像显示 MMT 关节中 500 kDa 葡聚糖的清除率显著降低。与 10 kDa 葡聚糖相比,500 kDa 葡聚糖在淋巴结和血浆中的药物蓄积量较低,而在存在骨关节炎的情况下,淋巴结中的药物蓄积量进一步降低。此外,与未处理关节相比,MMT 关节中的滑膜明显更厚,并且关节组织切片的图像分析显示 10 和 500 kDa 葡聚糖的跨滑膜分布不同。
大分子药物在关节炎关节中的滞留时间长于健康关节,而小分子药物在健康和关节炎关节中的清除速度相似。体内荧光成像、血浆和淋巴结浓度以及药物荧光的空间分布,确定了在未处理和关节炎疾病状态之间,高分子量药物清除率的差异。这些发现可能与诱导关节炎的关节滑膜增厚有关,并支持关节病理状态变化可能会影响关节内药物输送效果的概念。